Literature DB >> 8887592

Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments)

A F Connors1, N V Dawson, C Thomas, F E Harrell, N Desbiens, W J Fulkerson, P Kussin, P Bellamy, L Goldman, W A Knaus.   

Abstract

In order to describe the outcomes of patients hospitalized with an acute exacerbation of severe chronic obstructive pulmonary disease (COPD) and determine the relationship between patient characteristics and length of survival, we studied a prospective cohort of 1,016 adult patients from five hospitals who were admitted with an exacerbation of COPD and a PaCO2 of 50 mm Hg or more. Patient characteristics and acute physiology were determined. Outcomes were evaluated over a 6 mo period. Although only 11% of the patients died during the index hospital stay, the 60-d, 180-d, 1-yr, and 2-yr mortality was high (20%, 33%, 43%, and 49%, respectively). The median cost of the index hospital stay was $7,100 ($4,100 to $16,000; interquartile range). The median length of the index hospital stay was 9 d (5 to 15 d). After discharge, 446 patients were readmitted 754 times in the next 6 mo. At 6 mo, only 26% of the cohort were both alive and able to report a good, very good, or excellent quality of life. Survival time was independently related to severity of illness, body mass index (BMI), age, prior functional status, PaO2/FI(O2), congestive heart failure, serum albumin, and the presence of cor pulmonale. Patients and caregivers should be aware of the likelihood of poor outcomes following hospitalization for exacerbation of COPD associated with hypercarbia.

Entities:  

Mesh:

Year:  1996        PMID: 8887592     DOI: 10.1164/ajrccm.154.4.8887592

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  320 in total

Review 1.  Home treatment of COPD exacerbations.

Authors:  D S Postma; N H Ten Hacken; H A Kerstjens; G H Koëter
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Lung transplantation for chronic obstructive pulmonary disease: an exercise in quality rather than quantity?

Authors:  P A Corris
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 3.  Rationale for the use of non-invasive ventilation in chronic ventilatory failure.

Authors:  P M Turkington; M W Elliott
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

4.  Cor Pulmonale.

Authors: 
Journal:  Curr Treat Options Cardiovasc Med       Date:  2000-04

5.  Comparing three life-limiting diseases: does diagnosis matter or is sick, sick?

Authors:  Karen E Steinhauser; Robert M Arnold; Maren K Olsen; Jennifer Lindquist; Judith Hays; Laura L Wood; Allison M Burton; James A Tulsky
Journal:  J Pain Symptom Manage       Date:  2011-01-28       Impact factor: 3.612

Review 6.  Management of an acute exacerbation of copd: are we ignoring the evidence?

Authors:  M K Johnson; R D Stevenson
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

7.  The new contract: renaissance or requiem for general practice?

Authors:  Martin Marshall; Martin Roland
Journal:  Br J Gen Pract       Date:  2002-07       Impact factor: 5.386

8.  Length of ICU stay for chronic obstructive pulmonary disease varies among large community hospitals.

Authors:  Sean P Keenan; Peter Dodek; Keith Chan; Robert S Hogg; Kevin J P Craib; Aslam H Anis; John J Spinelli
Journal:  Intensive Care Med       Date:  2003-03-15       Impact factor: 17.440

9.  Integrated interdisciplinary care for patients with chronic obstructive pulmonary disease reduces emergency department visits, admissions and costs: a quality assurance study.

Authors:  Esther Dajczman; Chantal Robitaille; Pierre Ernst; Andrew Michael Hirsch; Norman Wolkove; David Small; Judy Bianco; Hartley Stern; Mark Palayew
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

Review 10.  Palliative care in chronic obstructive pulmonary disease: a review for clinicians.

Authors:  David A Seamark; Clare J Seamark; David M G Halpin
Journal:  J R Soc Med       Date:  2007-05       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.